Table 3 |
||||||||
|
Annual transition probabilities for ranibizumab and no ranibizumab treatment strategies for first two years |
||||||||
| Difference in number of letters read on logMAR chart at beginning and end of year |
||||||||
|
|
||||||||
| Ranibizumab treatment |
No ranibizumab treatment |
|||||||
|
|
||||||||
| Year |
15 |
0 |
-15 |
-30 |
15 |
0 |
-15 |
-30 |
|
|
||||||||
| 1 |
0.338 |
0.608 |
0.042 |
0.012 |
0.050 |
0.572 |
0.235 |
0.143 |
| 2 |
0.030 |
0.902 |
0.051 |
0.017 |
0.000 |
0.848 |
0.070 |
0.082 |
|
|
||||||||
|
Hurley et al. Cost Effectiveness and Resource Allocation 2008 6:12 doi:10.1186/1478-7547-6-12 |
||||||||
